BGI Group signed three Memoranda of Understanding (MOUs) ahead of the G20 Summit in Bali with the Indonesian Ministry of Health, the University of Indonesia and the Del Institute of Technology (Institut Teknologi Del). The agreements cover genomics development initiatives, construction of related laboratories, and joint research and personnel training.
The signings were witnessed by Coordinating Minister of Maritime and Investment Affairs of Indonesia, Luhut Binsar Pandjaitan, Indonesian Minister of Health, Budi Gunadi Sadikin, and Chairman and Co-Founder of BGI Group, Wang Jian.
Wang Jian also spoke at the “Tri Hita Karana (THK) Future Knowledge Summit,” an official G20 side event in Bali, on “DNA Cell Stomics For All In The Emerging Future.”
Genomics has been highlighted as a key component of Indonesia’s medical transformation strategy. On 14 August 2022, Indonesia launched its first national integrated biomedical program, the “Biomedical and Genome Science Initiative” (BGSi). MGI was selected as a technology provider for the first phase, which aims to establish a credible population database of 10,000 whole genomes. Working with local partner PT Bakti Energi Abadi, MGI will implement a total workflow using the ultra-high-throughput DNBSEQ-T7RS* sequencer, MGISP-960RS and MGISP-NE384RS automation systems, and the ZTRON data platform.
MGI’s DNBSEQ™ sequencing platform offers ultra-high throughput, low-cost, fully automated sequencing from sample to report. This will make gene sequencing more accessible, advance precision medicine, and accelerate progress in the human genome era.
With a mission to give global customers “the right to another choice,” MGI develops and promotes advanced life science tools to empower healthcare and contribute to building “a community with a shared future for mankind.”
*Note: StandardMPS and CoolMPS sequencing reagents and sequencers have regional availability restrictions as specified.
